TC
BIB icon

Truvestments Capital’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Truvestments Capital’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.2K Hold
125
– – ﹤0.01% 756
2025
Q4 		$9.97K Hold
125
– – ﹤0.01% 703
2025
Q3 		$7.45K Hold
125
– – ﹤0.01% 755
2025
Q2 		$5.73K Hold
125
– – ﹤0.01% 718
2025
Q1 		$6.02K Hold
125
– – ﹤0.01% 735
2024
Q4 		$6.33K Hold
125
– – ﹤0.01% 668
2024
Q3 		$7.97K Buy
+125
New +$8.07K ﹤0.01% 613
2024
Q2 		– Sell
-125
Closed -$7.19K – 278
2024
Q1 		$7.19K Hold
125
– – ﹤0.01% 521
2023
Q4 		$7.13K Hold
125
– – ﹤0.01% 546
2023
Q3 		$6K Hold
125
– – ﹤0.01% 494
2023
Q2 		$6.5K Sell
125
-25
-17% -$1.38K ﹤0.01% 502
2023
Q1 		$8.13K Sell
150
-10
-6% -$564 ﹤0.01% 456
2022
Q4 		$9.23K Sell
160
-30
-16% -$1.69K 0.01% 464
2022
Q3 		$9K Sell
190
-10
-5% -$533 0.01% 417
2022
Q2 		$10K Buy
+200
New +$10.2K 0.01% 409
2022
Q1 		– Sell
-200
Closed -$16K – 224
2021
Q4 		$16K Hold
200
– – 0.01% 361
2021
Q3 		$19K Hold
200
– – 0.01% 320
2021
Q2 		$20K Sell
200
-250
-56% -$21.8K 0.01% 319
2021
Q1 		$38K Buy
450
+200
+80% +$18.9K 0.02% 308
2020
Q4 		$22K Hold
250
– – 0.02% 348
2020
Q3 		$17K Hold
250
– – 0.02% 234
2020
Q2 		$18K Hold
250
– – 0.02% 316
2020
Q1 		$11K Buy
+250
New +$13.9K 0.01% 332
2019
Q4 		– Sell
-750
Closed -$32K – 188
2019
Q3 		$32K Hold
750
– – 0.02% 324
2019
Q2 		$39K Hold
750
– – 0.03% 313
2019
Q1 		$42K Buy
+750
New +$40.4K 0.03% 304
2018
Q3 		$64K Buy
+920
New +$60.1K 0.03% 332

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Truvestments Capital's BIB Position: Q1 2026 in Review

Truvestments Capital held its ProShares Ultra NASDAQ Biotechnology (BIB) position steady in Q1 2026 at 125 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #756.

Truvestments Capital first reported a position in BIB in Q3 2018 and has held it in 27 quarters since. The position peaked at $64K in Q3 2018. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

  • Truvestments Capital held 125 shares of ProShares Ultra NASDAQ Biotechnology worth $10.2K as of Q1 2026.
  • Truvestments Capital left its ProShares Ultra NASDAQ Biotechnology share count unchanged in Q1 2026.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #756 holding.
  • Truvestments Capital first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2018 and has held it in 27 quarters since.
  • Truvestments Capital's ProShares Ultra NASDAQ Biotechnology position peaked at $64K in Q3 2018.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.